Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

148.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 380
Open 148.04
Bid (Size) 145.05 (200)
Ask (Size) 148.00 (1,400)
Prev. Close 148.04
Today's Range 148.04 - 148.04
52wk Range 75.56 - 152.94
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
These drugmakers are poised to profit from their innovative engines. 
Via The Motley Fool
News headline image
Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗
Axsome (AXSM) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+69.5%
+69.5%
1 Month
+9.7%
+9.7%
3 Month
+19.0%
+19.0%
6 Month
+33.8%
+33.8%
1 Year
+48.7%
+48.7%

More News

Read More
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Where Axsome Therapeutics Stands With Analysts ↗
Via Benzinga
News headline image
2 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Via Chartmill
News headline image
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗
Via Benzinga
News headline image
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗
Via The Motley Fool
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗
Via The Motley Fool
News headline image
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts ↗
Via Benzinga
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings ↗
Via Benzinga
News headline image
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading ↗
Via Chartmill
News headline image
Axsome (AXSM) Q2 Revenue Soars 72% ↗
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 148.04
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 12/04/25 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 6.99B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.